| Literature DB >> 15584030 |
Aida M Bertoli-Avella1, José L Giroud-Benitez2, Ali Akyol3, Egberto Barbosa4, Onno Schaap1, Herma C van der Linde1, Emilia Martignoni5, Leonardo Lopiano6, Paolo Lamberti7, Emiliana Fincati8, Angelo Antonini9, Fabrizio Stocchi10, Pasquale Montagna11, Ferdinando Squitieri12, Paolo Marini13, Giovanni Abbruzzese14, Giovanni Fabbrini10, Roberto Marconi15, Alessio Dalla Libera16, Giorgio Trianni17, Marco Guidi18, Antonio De Gaetano19, Gustavo Boff Maegawa20, Antonino De Leo21, Virgilio Gallai22, Giulia de Rosa23, Nicola Vanacore24, Giuseppe Meco10, Cornelia M van Duijn1, Ben A Oostra1, Peter Heutink25, Vincenzo Bonifati1,10.
Abstract
A multiethnic series of patients with early-onset Parkinson's disease (EOP) was studied to assess the frequency and nature of parkin/PARK2 gene mutations and to investigate phenotype-genotype relationships. Forty-six EOP probands with an onset age of < 45 years, and 14 affected relatives were ascertained from Italy, Brazil, Cuba, and Turkey. The genetic screening included direct sequencing and exon dosage using a new, cost-effective, real-time polymerase chain reaction method. Mutations were found in 33% of the indexes overall, and in 53% of those with family history compatible with autosomal recessive inheritance. Fifteen parkin alterations (10 exon deletions and five point mutations) were identified, including four novel mutations: Arg402Cys, Cys418Arg, IVS11-3C > G, and exon 8-9-10 deletion. Homozygous mutations, two heterozygous mutations, and a single heterozygous mutation were found in 8, 6, and 1 patient, respectively. Heterozygous exon deletions represented 28% of the mutant alleles. The patients with parkin mutations showed significantly earlier onset, longer disease duration, more frequently symmetric onset, and slower disease progression than the patients without mutations, in agreement with previous studies. This study confirms the frequent involvement of parkin and the importance of genetic testing in the diagnostic work-up of EOP. Copyright 2004 Movement Disorder Society.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15584030 DOI: 10.1002/mds.20343
Source DB: PubMed Journal: Mov Disord ISSN: 0885-3185 Impact factor: 10.338